| Ticker | Action | Number of Shares Bought/Sold | Value of Shares Added/Sold | Average Price paid for previous share BUYs |
|---|
| 2413.T - M3, Inc. | HOLD | 0 @ JPY 15.4572 | JPY 0 | The current share valuation price of 2413.T based on adjusted close was JPY 15.4572. The average price that 2413.T shares were previous bought at was JPY 14.6321. The current market price is 5.6% higher than average price they were purchased at. The value of the holding in 2413.T has fallen by JPY 1,632 (USD $10) compared to the previous valuation of M3, Inc. |
| 4151.T - Kyowa Kirin Co., Ltd. | HOLD | 0 @ JPY 16.5652 | JPY 0 | The current share valuation price of 4151.T based on adjusted close was JPY 16.5652. The average price that 4151.T shares were previous bought at was JPY 15.6756. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in 4151.T has fallen by JPY 27,273 (USD $175) compared to the previous valuation of Kyowa Kirin Co., Ltd. |
| 4502.T - Takeda Pharmaceutical Company Limited | HOLD | 0 @ JPY 28.692 | JPY 0 | The current share valuation price of 4502.T based on adjusted close was JPY 28.692. The average price that 4502.T shares were previous bought at was JPY 28.7628. The current market price is -0.2% lower than average price they were purchased at. The value of the holding in 4502.T has increased by JPY 206 (USD $1) compared to the previous valuation of Takeda Pharmaceutical Company Limited however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| 4503.T - Astellas Pharma Inc. | HOLD | 0 @ JPY 12.7774 | JPY 0 | The current share valuation price of 4503.T based on adjusted close was JPY 12.7774. The average price that 4503.T shares were previous bought at was JPY 10.952. The current market price is 16.7% higher than average price they were purchased at. The value of the holding in 4503.T has fallen by JPY 1,887 (USD $12) compared to the previous valuation of Astellas Pharma Inc. |
| 4507.T - Shionogi & Co., Ltd. | HOLD | 0 @ JPY 16.942 | JPY 0 | The current share valuation price of 4507.T based on adjusted close was JPY 16.942. The average price that 4507.T shares were previous bought at was JPY 16.9132. The current market price is 0.2% higher than average price they were purchased at. The value of the holding in 4507.T has increased by JPY 119 (USD $1) compared to the previous valuation of Shionogi & Co., Ltd. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| 4519.T - Chugai Pharmaceutical Co., Ltd. | HOLD | 0 @ JPY 52.9069 | JPY 0 | The current share valuation price of 4519.T based on adjusted close was JPY 52.9069. The average price that 4519.T shares were previous bought at was JPY 46.8654. The current market price is 12.9% higher than average price they were purchased at. The value of the holding in 4519.T has increased by JPY 51,316 (USD $329) compared to the previous valuation of Chugai Pharmaceutical Co., Ltd. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| 4523.T - Eisai Co., Ltd. | HOLD | 0 @ JPY 30.1672 | JPY 0 | The current share valuation price of 4523.T based on adjusted close was JPY 30.1672. The average price that 4523.T shares were previous bought at was JPY 30.5058. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in 4523.T has fallen by JPY 22,873 (USD $147) compared to the previous valuation of Eisai Co., Ltd. |
| 4543.T - Terumo Corporation | HOLD | 0 @ JPY 15.309 | JPY 0 | The current share valuation price of 4543.T based on adjusted close was JPY 15.309. The average price that 4543.T shares were previous bought at was JPY 16.5412. The current market price is -7.4% lower than average price they were purchased at. The value of the holding in 4543.T has fallen by JPY 1,848 (USD $12) compared to the previous valuation of Terumo Corporation |
| 4568.T - Daiichi Sankyo Company, Limited | HOLD | 0 @ JPY 22.9394 | JPY 0 | The current share valuation price of 4568.T based on adjusted close was JPY 22.9394. The average price that 4568.T shares were previous bought at was JPY 27.437. The current market price is -16.4% lower than average price they were purchased at. The value of the holding in 4568.T has fallen by JPY 210,643 (USD $1,352) compared to the previous valuation of Daiichi Sankyo Company, Limited |
| 4578.T - Otsuka Holdings Co., Ltd. | HOLD | 0 @ JPY 58.2601 | JPY 0 | The current share valuation price of 4578.T based on adjusted close was JPY 58.2601. The average price that 4578.T shares were previous bought at was JPY 55.531. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in 4578.T has increased by JPY 9,990 (USD $64) compared to the previous valuation of Otsuka Holdings Co., Ltd. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| 6869.T - Sysmex Corporation | HOLD | 0 @ JPY 9.36644 | JPY 0 | The current share valuation price of 6869.T based on adjusted close was JPY 9.36644. The average price that 6869.T shares were previous bought at was JPY 12.0716. The current market price is -22.4% lower than average price they were purchased at. The value of the holding in 6869.T has fallen by JPY 1,070 (USD $7) compared to the previous valuation of Sysmex Corporation |
| 7733.T - Olympus Corporation | HOLD | 0 @ JPY 12.9094 | JPY 0 | The current share valuation price of 7733.T based on adjusted close was JPY 12.9094. The average price that 7733.T shares were previous bought at was JPY 12.7075. The current market price is 1.6% higher than average price they were purchased at. The value of the holding in 7733.T has fallen by JPY 3,877 (USD $25) compared to the previous valuation of Olympus Corporation |
| 7741.T - HOYA Corporation | HOLD | 0 @ JPY 151.255 | JPY 0 | The current share valuation price of 7741.T based on adjusted close was JPY 151.255. The average price that 7741.T shares were previous bought at was JPY 142.488. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in 7741.T has fallen by JPY 5,863 (USD $38) compared to the previous valuation of HOYA Corporation |
| A - Agilent Technologies Inc | HOLD | 0 @ USD 149.26 | USD 0 | The current share valuation price of A based on adjusted close was USD 149.26. The average price that A shares were previous bought at was USD 136.481. The current market price is 9.4% higher than average price they were purchased at. The value of the holding in A has increased by USD 24,931 compared to the previous valuation of Agilent Technologies Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ABBV - AbbVie Inc | HOLD | 0 @ USD 230.24 | USD 0 | The current share valuation price of ABBV based on adjusted close was USD 230.24. The average price that ABBV shares were previous bought at was USD 207.961. The current market price is 10.7% higher than average price they were purchased at. The value of the holding in ABBV has increased by USD 856,128 compared to the previous valuation of AbbVie Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ABT - Abbott Laboratories | HOLD | 0 @ USD 125.29 | USD 0 | The current share valuation price of ABT based on adjusted close was USD 125.29. The average price that ABT shares were previous bought at was USD 131.674. The current market price is -4.8% lower than average price they were purchased at. The value of the holding in ABT has fallen by USD 90,525 compared to the previous valuation of Abbott Laboratories |
| ALC.SW - | HOLD | 0 @ CHF 79.8102 | CHF 0 | The current share valuation price of ALC.SW based on adjusted close was CHF 79.8102. The average price that ALC.SW shares were previous bought at was CHF 77.8949. The current market price is 2.5% higher than average price they were purchased at. The value of the holding in ALC.SW has increased by CHF 102,383 (USD $127,523) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ALNY - Alnylam Pharmaceuticals Inc | HOLD | 0 @ USD 473.29 | USD 0 | The current share valuation price of ALNY based on adjusted close was USD 473.29. The average price that ALNY shares were previous bought at was USD 421.252. The current market price is 12.4% higher than average price they were purchased at. The value of the holding in ALNY has increased by USD 87,989 compared to the previous valuation of Alnylam Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AMGN - Amgen Inc | HOLD | 0 @ USD 345.42 | USD 0 | The current share valuation price of AMGN based on adjusted close was USD 345.42. The average price that AMGN shares were previous bought at was USD 303.018. The current market price is 14.0% higher than average price they were purchased at. The value of the holding in AMGN has increased by USD 256,914 compared to the previous valuation of Amgen Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ARGX.BR - Argenx SE | HOLD | 0 @ EUR 931.754 | EUR 0 | The current share valuation price of ARGX.BR based on adjusted close was EUR 931.754. The average price that ARGX.BR shares were previous bought at was EUR 849.225. The current market price is 9.7% higher than average price they were purchased at. The value of the holding in ARGX.BR has increased by EUR 113,312 (USD $131,758) compared to the previous valuation of Argenx SE however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| AZN.L - AstraZeneca PLC | HOLD | 0 @ GBP 182.562 | GBP 0 | The current share valuation price of AZN.L based on adjusted close was GBP 182.562. The average price that AZN.L shares were previous bought at was GBP 134.428. The current market price is 35.8% higher than average price they were purchased at. The value of the holding in AZN.L has increased by GBP 52,892 (USD $69,920) compared to the previous valuation of AstraZeneca PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BAX - Baxter International Inc | HOLD | 0 @ USD 18.89 | USD 0 | The current share valuation price of BAX based on adjusted close was USD 18.89. The average price that BAX shares were previous bought at was USD 19.3923. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in BAX has increased by USD 766 compared to the previous valuation of Baxter International Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BAYN.DE - Bayer AG | HOLD | 0 @ EUR 39.9407 | EUR 0 | The current share valuation price of BAYN.DE based on adjusted close was EUR 39.9407. The average price that BAYN.DE shares were previous bought at was EUR 31.6215. The current market price is 26.3% higher than average price they were purchased at. The value of the holding in BAYN.DE has increased by EUR 6,034 (USD $7,016) compared to the previous valuation of Bayer AG however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BDX - Becton Dickinson and Company | HOLD | 0 @ USD 193.57 | USD 0 | The current share valuation price of BDX based on adjusted close was USD 193.57. The average price that BDX shares were previous bought at was USD 184.068. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in BDX has increased by USD 19,195 compared to the previous valuation of Becton Dickinson and Company however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BIIB - Biogen Inc | HOLD | 0 @ USD 180.75 | USD 0 | The current share valuation price of BIIB based on adjusted close was USD 180.75. The average price that BIIB shares were previous bought at was USD 174.271. The current market price is 3.7% higher than average price they were purchased at. The value of the holding in BIIB has increased by USD 5,145 compared to the previous valuation of Biogen Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BIM.PA - BioMerieux | HOLD | 0 @ EUR 123.962 | EUR 0 | The current share valuation price of BIM.PA based on adjusted close was EUR 123.962. The average price that BIM.PA shares were previous bought at was EUR 126.888. The current market price is -2.3% lower than average price they were purchased at. The value of the holding in BIM.PA has fallen by EUR 2,370 (USD $2,756) compared to the previous valuation of BioMerieux |
| BMY - Bloomsbury Publishing Plc | HOLD | 0 @ USD 50.96 | USD 0 | The current share valuation price of BMY based on adjusted close was USD 50.96. The average price that BMY shares were previous bought at was USD 47.3933. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in BMY has increased by USD 337,652 compared to the previous valuation of Bloomsbury Publishing Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| BSX - Boston Scientific Corporation | HOLD | 0 @ USD 98.57 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 98.57. The average price that BSX shares were previous bought at was USD 101.08. The current market price is -2.5% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 15,050 compared to the previous valuation of Boston Scientific Corporation |
| BSX - MULSTRXSSXIMETFP | HOLD | 0 @ USD 98.57 | USD 0 | The current share valuation price of BSX based on adjusted close was USD 98.57. The average price that BSX shares were previous bought at was USD 101.08. The current market price is -2.5% lower than average price they were purchased at. The value of the holding in BSX has fallen by USD 15,050 compared to the previous valuation of MULSTRXSSXIMETFP |
| CAH - Cardinal Health Inc | HOLD | 0 @ USD 199.71 | USD 0 | The current share valuation price of CAH based on adjusted close was USD 199.71. The average price that CAH shares were previous bought at was USD 169.573. The current market price is 17.8% higher than average price they were purchased at. The value of the holding in CAH has fallen by USD 266,030 compared to the previous valuation of Cardinal Health Inc |
| CI - Cigna Corp | HOLD | 0 @ USD 270.32 | USD 0 | The current share valuation price of CI based on adjusted close was USD 270.32. The average price that CI shares were previous bought at was USD 290.418. The current market price is -6.9% lower than average price they were purchased at. The value of the holding in CI has fallen by USD 137,592 compared to the previous valuation of Cigna Corp |
| CNC - Concurrent Technologies Plc | HOLD | 0 @ USD 38.81 | USD 0 | The current share valuation price of CNC based on adjusted close was USD 38.81. The average price that CNC shares were previous bought at was USD 39.0959. The current market price is -0.7% lower than average price they were purchased at. USD 0 compared to the previous valuation of Concurrent Technologies Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| COH.AX - | HOLD | 0 @ AUD 180.936 | AUD 0 | The current share valuation price of COH.AX based on adjusted close was AUD 180.936. The average price that COH.AX shares were previous bought at was AUD 184.68. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in COH.AX has fallen by AUD 3,969 (USD $2,609) compared to the previous valuation of |
| COLO-B.CO - | HOLD | 0 @ DKK 90.3392 | DKK 0 | The current share valuation price of COLO-B.CO based on adjusted close was DKK 90.3392. The average price that COLO-B.CO shares were previous bought at was DKK 91.9921. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in COLO-B.CO has increased by DKK 31,248 (USD $4,865) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| COO - The Cooper Companies, Inc. Common Stock | HOLD | 0 @ USD 75.98 | USD 0 | The current share valuation price of COO based on adjusted close was USD 75.98. The average price that COO shares were previous bought at was USD 75.7419. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in COO has increased by USD 2,621 compared to the previous valuation of The Cooper Companies, Inc. Common Stock however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| COR - Cencora Inc. | HOLD | 0 @ USD 335.31 | USD 0 | The current share valuation price of COR based on adjusted close was USD 335.31. The average price that COR shares were previous bought at was USD 322.771. The current market price is 3.9% higher than average price they were purchased at. The value of the holding in COR has fallen by USD 564,004 compared to the previous valuation of Cencora Inc. |
| CSL.AX - | HOLD | 0 @ AUD 120.272 | AUD 0 | The current share valuation price of CSL.AX based on adjusted close was AUD 120.272. The average price that CSL.AX shares were previous bought at was AUD 119.833. The current market price is 0.4% higher than average price they were purchased at. The value of the holding in CSL.AX has fallen by AUD 5,678 (USD $3,733) compared to the previous valuation of |
| CVS - CVS Health Corp | HOLD | 0 @ USD 75 | USD 0 | The current share valuation price of CVS based on adjusted close was USD 75. The average price that CVS shares were previous bought at was USD 71.2654. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in CVS has fallen by USD 196,717 compared to the previous valuation of CVS Health Corp |
| DEMANT.CO - | HOLD | 0 @ DKK 33.0692 | DKK 0 | The current share valuation price of DEMANT.CO based on adjusted close was DKK 33.0692. The average price that DEMANT.CO shares were previous bought at was DKK 35.3933. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in DEMANT.CO has fallen by DKK 22,706 (USD $3,535) compared to the previous valuation of |
| DGX - Quest Diagnostics Incorporated | HOLD | 0 @ USD 182.61 | USD 0 | The current share valuation price of DGX based on adjusted close was USD 182.61. The average price that DGX shares were previous bought at was USD 182.08. The current market price is 0.3% higher than average price they were purchased at. The value of the holding in DGX has increased by USD 136 compared to the previous valuation of Quest Diagnostics Incorporated however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 210.347. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 86,978 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DHR - Danaher Corporation | HOLD | 0 @ USD 228.46 | USD 0 | The current share valuation price of DHR based on adjusted close was USD 228.46. The average price that DHR shares were previous bought at was USD 210.347. The current market price is 8.6% higher than average price they were purchased at. The value of the holding in DHR has increased by USD 86,978 compared to the previous valuation of Danaher Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DIM.PA - Sartorius Stedim Biotech | HOLD | 0 @ EUR 250.955 | EUR 0 | The current share valuation price of DIM.PA based on adjusted close was EUR 250.955. The average price that DIM.PA shares were previous bought at was EUR 221.291. The current market price is 13.4% higher than average price they were purchased at. The value of the holding in DIM.PA has increased by EUR 14,239 (USD $16,557) compared to the previous valuation of Sartorius Stedim Biotech however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| DXCM - DexCom Inc | HOLD | 0 @ USD 64.85 | USD 0 | The current share valuation price of DXCM based on adjusted close was USD 64.85. The average price that DXCM shares were previous bought at was USD 69.0446. The current market price is -6.1% lower than average price they were purchased at. The value of the holding in DXCM has increased by USD 4,647 compared to the previous valuation of DexCom Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| EL.PA - EssilorLuxottica SA | HOLD | 0 @ EUR 360.107 | EUR 0 | The current share valuation price of EL.PA based on adjusted close was EUR 360.107. The average price that EL.PA shares were previous bought at was EUR 343.222. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in EL.PA has increased by EUR 75,974 (USD $88,342) compared to the previous valuation of EssilorLuxottica SA however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 330.75 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 330.75. The average price that ELV shares were previous bought at was USD 379.389. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 5,917 compared to the previous valuation of Elevance Health Inc |
| ELV - Elevance Health Inc | HOLD | 0 @ USD 330.75 | USD 0 | The current share valuation price of ELV based on adjusted close was USD 330.75. The average price that ELV shares were previous bought at was USD 379.389. The current market price is -12.8% lower than average price they were purchased at. The value of the holding in ELV has fallen by USD 5,917 compared to the previous valuation of Elevance Health Inc |
| ERF.PA - Eurofins Scientific SE | HOLD | 0 @ EUR 68.313 | EUR 0 | The current share valuation price of ERF.PA based on adjusted close was EUR 68.313. The average price that ERF.PA shares were previous bought at was EUR 54.9711. The current market price is 24.3% higher than average price they were purchased at. The value of the holding in ERF.PA has fallen by EUR 2,454 (USD $2,853) compared to the previous valuation of Eurofins Scientific SE |
| EW - Edwards Lifesciences Corp | HOLD | 0 @ USD 83.98 | USD 0 | The current share valuation price of EW based on adjusted close was USD 83.98. The average price that EW shares were previous bought at was USD 78.9814. The current market price is 6.3% higher than average price they were purchased at. The value of the holding in EW has fallen by USD 69,669 compared to the previous valuation of Edwards Lifesciences Corp |
| FME.DE - Fresenius Medical Care AG | HOLD | 0 @ EUR 47.0425 | EUR 0 | The current share valuation price of FME.DE based on adjusted close was EUR 47.0425. The average price that FME.DE shares were previous bought at was EUR 50.6369. The current market price is -7.1% lower than average price they were purchased at. The value of the holding in FME.DE has fallen by EUR 2,358 (USD $2,742) compared to the previous valuation of Fresenius Medical Care AG |
| FPH.NZ - | HOLD | 0 @ NZD 22.1184 | NZD 0 | The current share valuation price of FPH.NZ based on adjusted close was NZD 22.1184. The average price that FPH.NZ shares were previous bought at was NZD 21.0994. The current market price is 4.8% higher than average price they were purchased at. The value of the holding in FPH.NZ has increased by NZD 3,592 (USD $2,062) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| FRE.DE - Fresenius SE & Co KGaA | HOLD | 0 @ EUR 55.2638 | EUR 0 | The current share valuation price of FRE.DE based on adjusted close was EUR 55.2638. The average price that FRE.DE shares were previous bought at was EUR 52.7009. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in FRE.DE has increased by EUR 8,175 (USD $9,506) compared to the previous valuation of Fresenius SE & Co KGaA however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GALD.SW - | HOLD | 0 @ CHF 203.834 | CHF 0 | The current share valuation price of GALD.SW based on adjusted close was CHF 203.834. The average price that GALD.SW shares were previous bought at was CHF 184.735. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in GALD.SW has increased by CHF 65,921 (USD $82,108) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GEHC - GE HealthCare Technologies Inc. | HOLD | 0 @ USD 83.59 | USD 0 | The current share valuation price of GEHC based on adjusted close was USD 83.59. The average price that GEHC shares were previous bought at was USD 78.1556. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in GEHC has increased by USD 32,581 compared to the previous valuation of GE HealthCare Technologies Inc. however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GILD - Guild Esports Plc | HOLD | 0 @ USD 125 | USD 0 | The current share valuation price of GILD based on adjusted close was USD 125. The average price that GILD shares were previous bought at was USD 116.84. The current market price is 7.0% higher than average price they were purchased at. The value of the holding in GILD has increased by USD 159,215 compared to the previous valuation of Guild Esports Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| GMAB.CO - | HOLD | 0 @ DKK 315.859 | DKK 0 | The current share valuation price of GMAB.CO based on adjusted close was DKK 315.859. The average price that GMAB.CO shares were previous bought at was DKK 286.349. The current market price is 10.3% higher than average price they were purchased at. The value of the holding in GMAB.CO has fallen by DKK 2,976 (USD $463) compared to the previous valuation of |
| GRF.MC - Grifols SA | HOLD | 0 @ EUR 12.0813 | EUR 0 | The current share valuation price of GRF.MC based on adjusted close was EUR 12.0813. The average price that GRF.MC shares were previous bought at was EUR 13.0922. The current market price is -7.7% lower than average price they were purchased at. The value of the holding in GRF.MC has fallen by EUR 514 (USD $598) compared to the previous valuation of Grifols SA |
| GSK.L - GlaxoSmithKline PLC | HOLD | 0 @ GBP 24.4366 | GBP 0 | The current share valuation price of GSK.L based on adjusted close was GBP 24.4366. The average price that GSK.L shares were previous bought at was GBP 23.2984. The current market price is 4.9% higher than average price they were purchased at. The value of the holding in GSK.L has increased by GBP 88,744 (USD $117,315) compared to the previous valuation of GlaxoSmithKline PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HCA - HCA Holdings Inc | HOLD | 0 @ USD 486.77 | USD 0 | The current share valuation price of HCA based on adjusted close was USD 486.77. The average price that HCA shares were previous bought at was USD 446.536. The current market price is 9.0% higher than average price they were purchased at. The value of the holding in HCA has fallen by USD 54,959 compared to the previous valuation of HCA Holdings Inc |
| HIK.L - | HOLD | 0 @ GBP 21.0638 | GBP 0 | The current share valuation price of HIK.L based on adjusted close was GBP 21.0638. The average price that HIK.L shares were previous bought at was GBP 22.8357. The current market price is -7.8% lower than average price they were purchased at. The value of the holding in HIK.L has increased by GBP 3,195 (USD $4,224) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HLN.L - Haleon PLC | HOLD | 0 @ GBP 4.81401 | GBP 0 | The current share valuation price of HLN.L based on adjusted close was GBP 4.81401. The average price that HLN.L shares were previous bought at was GBP 4.89079. The current market price is -1.6% lower than average price they were purchased at. The value of the holding in HLN.L has fallen by GBP 16,846 (USD $22,270) compared to the previous valuation of Haleon PLC |
| HOLX - Hologic Inc | HOLD | 0 @ USD 75.01 | USD 0 | The current share valuation price of HOLX based on adjusted close was USD 75.01. The average price that HOLX shares were previous bought at was USD 70.4987. The current market price is 6.4% higher than average price they were purchased at. The value of the holding in HOLX has increased by USD 14,776 compared to the previous valuation of Hologic Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HUM - Hummingbird Resources PLC | HOLD | 0 @ USD 256.92 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 256.92. The average price that HUM shares were previous bought at was USD 301.5. The current market price is -14.8% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 261,097 compared to the previous valuation of Hummingbird Resources PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| HUM - Humana Inc | HOLD | 0 @ USD 256.92 | USD 0 | The current share valuation price of HUM based on adjusted close was USD 256.92. The average price that HUM shares were previous bought at was USD 301.5. The current market price is -14.8% lower than average price they were purchased at. The value of the holding in HUM has increased by USD 261,097 compared to the previous valuation of Humana Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IDXX - IDEXX Laboratories Inc | HOLD | 0 @ USD 725.93 | USD 0 | The current share valuation price of IDXX based on adjusted close was USD 725.93. The average price that IDXX shares were previous bought at was USD 617.871. The current market price is 17.5% higher than average price they were purchased at. The value of the holding in IDXX has fallen by USD 102,891 compared to the previous valuation of IDEXX Laboratories Inc |
| ILMN - Illumina Inc | HOLD | 0 @ USD 127.95 | USD 0 | The current share valuation price of ILMN based on adjusted close was USD 127.95. The average price that ILMN shares were previous bought at was USD 105.053. The current market price is 21.8% higher than average price they were purchased at. The value of the holding in ILMN has increased by USD 1,283 compared to the previous valuation of Illumina Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| INCY - Incyte Corporation | HOLD | 0 @ USD 101.5 | USD 0 | The current share valuation price of INCY based on adjusted close was USD 101.5. The average price that INCY shares were previous bought at was USD 105.014. The current market price is -3.3% lower than average price they were purchased at. The value of the holding in INCY has increased by USD 739 compared to the previous valuation of Incyte Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| INSM - Insmed Inc | HOLD | 0 @ USD 206.78 | USD 0 | The current share valuation price of INSM based on adjusted close was USD 206.78. The average price that INSM shares were previous bought at was USD 207.77. The current market price is -0.5% lower than average price they were purchased at. The value of the holding in INSM has increased by USD 2,037 compared to the previous valuation of Insmed Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| IPN.PA - Ipsen SA | HOLD | 0 @ EUR 142.037 | EUR 0 | The current share valuation price of IPN.PA based on adjusted close was EUR 142.037. The average price that IPN.PA shares were previous bought at was EUR 136.194. The current market price is 4.3% higher than average price they were purchased at. The value of the holding in IPN.PA has fallen by EUR 2,746 (USD $3,193) compared to the previous valuation of Ipsen SA |
| IQV - IQVIA Holdings Inc | HOLD | 0 @ USD 227.24 | USD 0 | The current share valuation price of IQV based on adjusted close was USD 227.24. The average price that IQV shares were previous bought at was USD 201.584. The current market price is 12.7% higher than average price they were purchased at. The value of the holding in IQV has increased by USD 66,635 compared to the previous valuation of IQVIA Holdings Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ISRG - Intuitive Surgical Inc | HOLD | 0 @ USD 569.71 | USD 0 | The current share valuation price of ISRG based on adjusted close was USD 569.71. The average price that ISRG shares were previous bought at was USD 538.898. The current market price is 5.7% higher than average price they were purchased at. The value of the holding in ISRG has increased by USD 48,749 compared to the previous valuation of Intuitive Surgical Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| JNJ - Johnson & Johnson | HOLD | 0 @ USD 205.33 | USD 0 | The current share valuation price of JNJ based on adjusted close was USD 205.33. The average price that JNJ shares were previous bought at was USD 169.964. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in JNJ has fallen by USD 13,651 compared to the previous valuation of Johnson & Johnson |
| LH - Laboratory Corporation of America Holdings | HOLD | 0 @ USD 265.76 | USD 0 | The current share valuation price of LH based on adjusted close was USD 265.76. The average price that LH shares were previous bought at was USD 263.984. The current market price is 0.7% higher than average price they were purchased at. The value of the holding in LH has fallen by USD 295 compared to the previous valuation of Laboratory Corporation of America Holdings |
| LLY - Eli Lilly and Company | HOLD | 0 @ USD 1033.56 | USD 0 | The current share valuation price of LLY based on adjusted close was USD 1033.56. The average price that LLY shares were previous bought at was USD 851.851. The current market price is 21.3% higher than average price they were purchased at. The value of the holding in LLY has fallen by USD 828,508 compared to the previous valuation of Eli Lilly and Company |
| LONN.SW - | HOLD | 0 @ CHF 691.438 | CHF 0 | The current share valuation price of LONN.SW based on adjusted close was CHF 691.438. The average price that LONN.SW shares were previous bought at was CHF 675.177. The current market price is 2.4% higher than average price they were purchased at. The value of the holding in LONN.SW has increased by CHF 4,293 (USD $5,347) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MCK - McKesson Corporation | HOLD | 0 @ USD 805.37 | USD 0 | The current share valuation price of MCK based on adjusted close was USD 805.37. The average price that MCK shares were previous bought at was USD 782.624. The current market price is 2.9% higher than average price they were purchased at. The value of the holding in MCK has fallen by USD 379,207 compared to the previous valuation of McKesson Corporation |
| MDT - Medtronic PLC | HOLD | 0 @ USD 101.97 | USD 0 | The current share valuation price of MDT based on adjusted close was USD 101.97. The average price that MDT shares were previous bought at was USD 97.7117. The current market price is 4.4% higher than average price they were purchased at. The value of the holding in MDT has fallen by USD 2,038 compared to the previous valuation of Medtronic PLC |
| MRK - Marks Electrical Group PLC | HOLD | 0 @ USD 102.27 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 102.27. The average price that MRK shares were previous bought at was USD 91.0433. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 216,939 compared to the previous valuation of Marks Electrical Group PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MRK - Merck & Company Inc | HOLD | 0 @ USD 102.27 | USD 0 | The current share valuation price of MRK based on adjusted close was USD 102.27. The average price that MRK shares were previous bought at was USD 91.0433. The current market price is 12.3% higher than average price they were purchased at. The value of the holding in MRK has increased by USD 216,939 compared to the previous valuation of Merck & Company Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MRK.DE - Merck KGaA | HOLD | 0 @ EUR 139.821 | EUR 0 | The current share valuation price of MRK.DE based on adjusted close was EUR 139.821. The average price that MRK.DE shares were previous bought at was EUR 130.796. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in MRK.DE has increased by EUR 11,410 (USD $13,267) compared to the previous valuation of Merck KGaA however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| MTD - Mettler-Toledo International Inc | HOLD | 0 @ USD 1434.88 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1434.88. The average price that MTD shares were previous bought at was USD 1464.54. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 28,575 compared to the previous valuation of Mettler-Toledo International Inc |
| MTD - AMUNDI EUR GOV 710 | HOLD | 0 @ USD 1434.88 | USD 0 | The current share valuation price of MTD based on adjusted close was USD 1434.88. The average price that MTD shares were previous bought at was USD 1464.54. The current market price is -2.0% lower than average price they were purchased at. The value of the holding in MTD has fallen by USD 28,575 compared to the previous valuation of AMUNDI EUR GOV 710 |
| NBIX - Neurocrine Biosciences Inc | HOLD | 0 @ USD 151.96 | USD 0 | The current share valuation price of NBIX based on adjusted close was USD 151.96. The average price that NBIX shares were previous bought at was USD 141.389. The current market price is 7.5% higher than average price they were purchased at. The value of the holding in NBIX has fallen by USD 985 compared to the previous valuation of Neurocrine Biosciences Inc |
| NOVN.SW - | HOLD | 0 @ CHF 134.141 | CHF 0 | The current share valuation price of NOVN.SW based on adjusted close was CHF 134.141. The average price that NOVN.SW shares were previous bought at was CHF 122.898. The current market price is 9.1% higher than average price they were purchased at. The value of the holding in NOVN.SW has increased by CHF 529,230 (USD $659,181) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| NOVO-B.CO - Novo Nordisk A/S | HOLD | 0 @ DKK 47.4335 | DKK 0 | The current share valuation price of NOVO-B.CO based on adjusted close was DKK 47.4335. The average price that NOVO-B.CO shares were previous bought at was DKK 55.3991. The current market price is -14.4% lower than average price they were purchased at. The value of the holding in NOVO-B.CO has fallen by DKK 84,273 (USD $13,121) compared to the previous valuation of Novo Nordisk A/S |
| NTRA - Natera Inc | HOLD | 0 @ USD 238.21 | USD 0 | The current share valuation price of NTRA based on adjusted close was USD 238.21. The average price that NTRA shares were previous bought at was USD 176.34. The current market price is 35.1% higher than average price they were purchased at. The value of the holding in NTRA has increased by USD 4,925 compared to the previous valuation of Natera Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ORNBV.HE - Orion Oyj | HOLD | 0 @ EUR 70.3188 | EUR 0 | The current share valuation price of ORNBV.HE based on adjusted close was EUR 70.3188. The average price that ORNBV.HE shares were previous bought at was EUR 67.5102. The current market price is 4.2% higher than average price they were purchased at. The value of the holding in ORNBV.HE has fallen by EUR 3,839 (USD $4,464) compared to the previous valuation of Orion Oyj |
| PFE - Pfizer Inc | HOLD | 0 @ USD 25.57 | USD 0 | The current share valuation price of PFE based on adjusted close was USD 25.57. The average price that PFE shares were previous bought at was USD 24.7817. The current market price is 3.2% higher than average price they were purchased at. The value of the holding in PFE has increased by USD 107,077 compared to the previous valuation of Pfizer Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| PHIA.AS - Koninklijke Philips NV | HOLD | 0 @ EUR 28.0692 | EUR 0 | The current share valuation price of PHIA.AS based on adjusted close was EUR 28.0692. The average price that PHIA.AS shares were previous bought at was EUR 26.6894. The current market price is 5.2% higher than average price they were purchased at. The value of the holding in PHIA.AS has fallen by EUR 898 (USD $1,044) compared to the previous valuation of Koninklijke Philips NV |
| PME.AX - | HOLD | 0 @ AUD 167.794 | AUD 0 | The current share valuation price of PME.AX based on adjusted close was AUD 167.794. The average price that PME.AX shares were previous bought at was AUD 178.839. The current market price is -6.2% lower than average price they were purchased at. The value of the holding in PME.AX has fallen by AUD 4,431 (USD $2,913) compared to the previous valuation of |
| PODD - Insulet Corporation | HOLD | 0 @ USD 307.56 | USD 0 | The current share valuation price of PODD based on adjusted close was USD 307.56. The average price that PODD shares were previous bought at was USD 333.823. The current market price is -7.9% lower than average price they were purchased at. The value of the holding in PODD has fallen by USD 4,321 compared to the previous valuation of Insulet Corporation |
| QIA.DE - QIAGEN NV | HOLD | 0 @ EUR 46.5527 | EUR 0 | The current share valuation price of QIA.DE based on adjusted close was EUR 46.5527. The average price that QIA.DE shares were previous bought at was EUR 45.7321. The current market price is 1.8% higher than average price they were purchased at. The value of the holding in QIA.DE has fallen by EUR 30,208 (USD $35,126) compared to the previous valuation of QIAGEN NV |
| REC.MI - Recordati Industria Chimica e Farmaceutica SpA | HOLD | 0 @ EUR 57.6778 | EUR 0 | The current share valuation price of REC.MI based on adjusted close was EUR 57.6778. The average price that REC.MI shares were previous bought at was EUR 58.3969. The current market price is -1.2% lower than average price they were purchased at. The value of the holding in REC.MI has increased by EUR 977 (USD $1,136) compared to the previous valuation of Recordati Industria Chimica e Farmaceutica SpA however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| REGN - Regeneron Pharmaceuticals Inc | HOLD | 0 @ USD 723.67 | USD 0 | The current share valuation price of REGN based on adjusted close was USD 723.67. The average price that REGN shares were previous bought at was USD 714.362. The current market price is 1.3% higher than average price they were purchased at. The value of the holding in REGN has fallen by USD 124,809 compared to the previous valuation of Regeneron Pharmaceuticals Inc |
| RMD - ResMed Inc | HOLD | 0 @ USD 251.44 | USD 0 | The current share valuation price of RMD based on adjusted close was USD 251.44. The average price that RMD shares were previous bought at was USD 256.028. The current market price is -1.8% lower than average price they were purchased at. The value of the holding in RMD has increased by USD 2,435 compared to the previous valuation of ResMed Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RO.SW - | HOLD | 0 @ CHF 404.671 | CHF 0 | The current share valuation price of RO.SW based on adjusted close was CHF 404.671. The average price that RO.SW shares were previous bought at was CHF 343.703. The current market price is 17.7% higher than average price they were purchased at. The value of the holding in RO.SW has increased by CHF 25,048 (USD $31,198) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ROG.SW - | HOLD | 0 @ CHF 391.932 | CHF 0 | The current share valuation price of ROG.SW based on adjusted close was CHF 391.932. The average price that ROG.SW shares were previous bought at was CHF 360.262. The current market price is 8.8% higher than average price they were purchased at. The value of the holding in ROG.SW has increased by CHF 114,594 (USD $142,732) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| RPRX - Royalty Pharma Plc | HOLD | 0 @ USD 39.6 | USD 0 | The current share valuation price of RPRX based on adjusted close was USD 39.6. The average price that RPRX shares were previous bought at was USD 37.0444. The current market price is 6.9% higher than average price they were purchased at. The value of the holding in RPRX has increased by USD 586 compared to the previous valuation of Royalty Pharma Plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SAN.PA - Sanofi SA | HOLD | 0 @ EUR 99.8691 | EUR 0 | The current share valuation price of SAN.PA based on adjusted close was EUR 99.8691. The average price that SAN.PA shares were previous bought at was EUR 99.0728. The current market price is 0.8% higher than average price they were purchased at. The value of the holding in SAN.PA has fallen by EUR 6,618 (USD $7,695) compared to the previous valuation of Sanofi SA |
| SDZ.SW - | HOLD | 0 @ CHF 71.5668 | CHF 0 | The current share valuation price of SDZ.SW based on adjusted close was CHF 71.5668. The average price that SDZ.SW shares were previous bought at was CHF 58.4938. The current market price is 22.3% higher than average price they were purchased at. The value of the holding in SDZ.SW has increased by CHF 3,224 (USD $4,016) compared to the previous valuation of however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SHL.AX - | HOLD | 0 @ AUD 15.2534 | AUD 0 | The current share valuation price of SHL.AX based on adjusted close was AUD 15.2534. The average price that SHL.AX shares were previous bought at was AUD 15.0324. The current market price is 1.5% higher than average price they were purchased at. The value of the holding in SHL.AX has fallen by AUD 4,875 (USD $3,205) compared to the previous valuation of |
| SHL.DE - Siemens Healthineers AG | HOLD | 0 @ EUR 49.3632 | EUR 0 | The current share valuation price of SHL.DE based on adjusted close was EUR 49.3632. The average price that SHL.DE shares were previous bought at was EUR 53.3465. The current market price is -7.5% lower than average price they were purchased at. The value of the holding in SHL.DE has fallen by EUR 1,157 (USD $1,345) compared to the previous valuation of Siemens Healthineers AG |
| SIG.AX - | HOLD | 0 @ AUD 1.8473 | AUD 0 | The current share valuation price of SIG.AX based on adjusted close was AUD 1.8473. The average price that SIG.AX shares were previous bought at was AUD 1.89692. The current market price is -2.6% lower than average price they were purchased at. The value of the holding in SIG.AX has fallen by AUD 12,004 (USD $7,891) compared to the previous valuation of |
| SN.L - Smith & Nephew PLC | HOLD | 0 @ GBP 16.4444 | GBP 0 | The current share valuation price of SN.L based on adjusted close was GBP 16.4444. The average price that SN.L shares were previous bought at was GBP 17.3873. The current market price is -5.4% lower than average price they were purchased at. The value of the holding in SN.L has increased by GBP 2,664 (USD $3,522) compared to the previous valuation of Smith & Nephew PLC however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| SOBI.ST - | HOLD | 0 @ SEK 35.089 | SEK 0 | The current share valuation price of SOBI.ST based on adjusted close was SEK 35.089. The average price that SOBI.ST shares were previous bought at was SEK 33.0478. The current market price is 6.2% higher than average price they were purchased at. The value of the holding in SOBI.ST has fallen by SEK 8,557 (USD $908) compared to the previous valuation of |
| SOLV - Solventum Corp. | HOLD | 0 @ USD 85.2501 | USD 0 | The current share valuation price of SOLV based on adjusted close was USD 85.2501. The average price that SOLV shares were previous bought at was USD 72.8763. The current market price is 17.0% higher than average price they were purchased at. The value of the holding in SOLV has fallen by USD 1,326 compared to the previous valuation of Solventum Corp. |
| SOON.SW - | HOLD | 0 @ CHF 247.674 | CHF 0 | The current share valuation price of SOON.SW based on adjusted close was CHF 247.674. The average price that SOON.SW shares were previous bought at was CHF 273.01. The current market price is -9.3% lower than average price they were purchased at. The value of the holding in SOON.SW has fallen by CHF 59,823 (USD $74,512) compared to the previous valuation of |
| SRT3.DE - Sartorius AG | HOLD | 0 @ EUR 301.683 | EUR 0 | The current share valuation price of SRT3.DE based on adjusted close was EUR 301.683. The average price that SRT3.DE shares were previous bought at was EUR 257.023. The current market price is 17.4% higher than average price they were purchased at. The value of the holding in SRT3.DE has increased by EUR 90,912 (USD $105,712) compared to the previous valuation of Sartorius AG however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| STE - STERIS plc | HOLD | 0 @ USD 259.4 | USD 0 | The current share valuation price of STE based on adjusted close was USD 259.4. The average price that STE shares were previous bought at was USD 228.065. The current market price is 13.7% higher than average price they were purchased at. The value of the holding in STE has increased by USD 3,304 compared to the previous valuation of STERIS plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| STMN.SW - | HOLD | 0 @ CHF 113.533 | CHF 0 | The current share valuation price of STMN.SW based on adjusted close was CHF 113.533. The average price that STMN.SW shares were previous bought at was CHF 121.502. The current market price is -6.6% lower than average price they were purchased at. The value of the holding in STMN.SW has fallen by CHF 5,458 (USD $6,798) compared to the previous valuation of |
| SYK - Stryker Corporation | HOLD | 0 @ USD 365.95 | USD 0 | The current share valuation price of SYK based on adjusted close was USD 365.95. The average price that SYK shares were previous bought at was USD 370.188. The current market price is -1.1% lower than average price they were purchased at. The value of the holding in SYK has fallen by USD 11,576 compared to the previous valuation of Stryker Corporation |
| TEVA - Teva Pharma Industries Ltd ADR | HOLD | 0 @ USD 27.83 | USD 0 | The current share valuation price of TEVA based on adjusted close was USD 27.83. The average price that TEVA shares were previous bought at was USD 19.447. The current market price is 43.1% higher than average price they were purchased at. The value of the holding in TEVA has increased by USD 24,155 compared to the previous valuation of Teva Pharma Industries Ltd ADR however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| TMO - Time Out Group plc | HOLD | 0 @ USD 580.45 | USD 0 | The current share valuation price of TMO based on adjusted close was USD 580.45. The average price that TMO shares were previous bought at was USD 480.381. The current market price is 20.8% higher than average price they were purchased at. The value of the holding in TMO has increased by USD 1,744 compared to the previous valuation of Time Out Group plc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| UCB.BR - UCB SA | HOLD | 0 @ EUR 279.643 | EUR 0 | The current share valuation price of UCB.BR based on adjusted close was EUR 279.643. The average price that UCB.BR shares were previous bought at was EUR 209.407. The current market price is 33.5% higher than average price they were purchased at. The value of the holding in UCB.BR has fallen by EUR 51,616 (USD $60,019) compared to the previous valuation of UCB SA |
| UNH - UnitedHealth Group Incorporated | HOLD | 0 @ USD 339.71 | USD 0 | The current share valuation price of UNH based on adjusted close was USD 339.71. The average price that UNH shares were previous bought at was USD 424.05. The current market price is -19.9% lower than average price they were purchased at. The value of the holding in UNH has increased by USD 1,044,500 compared to the previous valuation of UnitedHealth Group Incorporated however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| UTHR - United Therapeutics Corporation | HOLD | 0 @ USD 480.96 | USD 0 | The current share valuation price of UTHR based on adjusted close was USD 480.96. The average price that UTHR shares were previous bought at was USD 430.316. The current market price is 11.8% higher than average price they were purchased at. The value of the holding in UTHR has increased by USD 6,274 compared to the previous valuation of United Therapeutics Corporation however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VEEV - Veeva Systems Inc Class A | HOLD | 0 @ USD 241.33 | USD 0 | The current share valuation price of VEEV based on adjusted close was USD 241.33. The average price that VEEV shares were previous bought at was USD 282.568. The current market price is -14.6% lower than average price they were purchased at. The value of the holding in VEEV has increased by USD 33,061 compared to the previous valuation of Veeva Systems Inc Class A however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| VRTX - Vertex Pharmaceuticals Inc | HOLD | 0 @ USD 463.13 | USD 0 | The current share valuation price of VRTX based on adjusted close was USD 463.13. The average price that VRTX shares were previous bought at was USD 422.613. The current market price is 9.6% higher than average price they were purchased at. The value of the holding in VRTX has increased by USD 935,976 compared to the previous valuation of Vertex Pharmaceuticals Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| WAT - Waters Corporation | HOLD | 0 @ USD 397.62 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 397.62. The average price that WAT shares were previous bought at was USD 343.572. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 15,817 compared to the previous valuation of Waters Corporation |
| WAT - MULETFWATIMETFP | HOLD | 0 @ USD 397.62 | USD 0 | The current share valuation price of WAT based on adjusted close was USD 397.62. The average price that WAT shares were previous bought at was USD 343.572. The current market price is 15.7% higher than average price they were purchased at. The value of the holding in WAT has fallen by USD 15,817 compared to the previous valuation of MULETFWATIMETFP |
| WST - West Pharmaceutical Services Inc | HOLD | 0 @ USD 284.31 | USD 0 | The current share valuation price of WST based on adjusted close was USD 284.31. The average price that WST shares were previous bought at was USD 268.208. The current market price is 6.0% higher than average price they were purchased at. The value of the holding in WST has increased by USD 17,326 compared to the previous valuation of West Pharmaceutical Services Inc however if the holding was sold on 2025-12-03 this would crystalise an overall loss. |
| ZBH - Zimmer Biomet Holdings Inc | HOLD | 0 @ USD 93.1 | USD 0 | The current share valuation price of ZBH based on adjusted close was USD 93.1. The average price that ZBH shares were previous bought at was USD 97.5443. The current market price is -4.6% lower than average price they were purchased at. The value of the holding in ZBH has fallen by USD 4,474 compared to the previous valuation of Zimmer Biomet Holdings Inc |
| ZTS - Zoetis Inc | HOLD | 0 @ USD 122.57 | USD 0 | The current share valuation price of ZTS based on adjusted close was USD 122.57. The average price that ZTS shares were previous bought at was USD 138.556. The current market price is -11.5% lower than average price they were purchased at. The value of the holding in ZTS has fallen by USD 163,769 compared to the previous valuation of Zoetis Inc |